Answers are grounded in this paper and cite their sources.
Demonstrates pain relief and cartilage protection in an osteoarthritis model, suggesting FIR as a novel therapeutic strategy.
This study investigated the anti-osteoclastic and chondroprotective effects of far-infrared (FIR) therapy in osteoarthritis (OA), focusing on its ability to modulate pathological osteoclast (OC) activation and subchondral bone remodeling. A monosodium iodoacetate (MIA)-induced OA rat model was used, and FIR's therapeutic potential was evaluated through longitudinal assessment of nociception (von Frey test), cartilage integrity (histomorphometry: H&E, TRAP, and safranin O/fast green staining), and subchondral microstructure (micro-CT). Complementary in vitro analyses of RANKL-stimulated osteoclastogenesis were performed, including transcriptomic profiling, cytoskeletal visualization, and proteomic validation. FIR intervention (30/60 min daily) significantly attenuated OA progression, demonstrating: (1) In vivo assessments demonstrated FIR produced time-dependent pain alleviation, with gradual relief observed over the course of treatment (P < 0.05). Early and mid-term (days 7/14) improvements were more pronounced, particularly in bone mineral density, cartilage integrity, and subchondral bone osteoclastogenesis suppression (P < 0.01). These effects diminished during the late intervention stage (days 28; P < 0.05). (2) Cellular studies showed FIR inhibited RANKL-mediated OC differentiation, as evidenced by reduced TRAP activity and downregulation of OC-specific markers (P < 0.05). (3) Transcriptomic analysis identified actin cytoskeleton reorganization and OC differentiation pathways as primary targets of FIR intervention. This finding was supported by disrupting F-actin ring formation and modulating key regulatory proteins via MAPK/c-Fos/NFATc1 signaling (P < 0.05). Our findings establish FIR therapy as an effective physical pharmacology strategy for OA management. It simultaneously addresses nociception, cartilage degeneration, and pathological bone remodeling through selective targeting of OC cytoskelet.
No takes yet. Share an insight, caveat, or question.
Qin et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: